Pittsburgh-based health insurance and hospital giant Highmark Health has had a challenging year so far, with net income in the first nine months of the year up more than 20%, but operating income sliding more than 30% compared to a year ago.
Total Highmark Health revenue for the nine months ending Sept. 30 rose 8.86% to $22.1 billion and net income was up 22.73% to $529 million, while the company’s operating gain slid 32.2% to $273 million compared to a year ago, according to financial disclosures released Tuesday.
Carl Daley, chief financial officer for Highmark Health, blamed the uneven results on “cost pressures and headwinds” in health care.
“These pressures developed earlier in the year, but they accelerated during the third quarter of 2024,” Mr. Daley said in a prepared statement.
“As a result we saw some deterioration in our operating gain primarily related to high prescription drug costs, the ongoing impact of Medicaid redeterminations and the upward trend in health care utilization.”
In remarks Tuesday, Mr. Daley said the pressures, which affect commercial, Medicaid and Medicare Advantage customers, were expected to continue.
Read More
“We expect that pressure to continue into the fourth quarter and into the next year,” he said. “We are not immune to what’s going on in the broader industry.”
Highmark’s Blue Cross Blue Shield health insurance business segment reported an operating decrease of 36% to $275 million on $16.6 billion in revenue for the most recent nine months. That compares to $430 million for the same period in 2023.
High prescription drug costs — especially for the popular GLP-1s, which are used to treat diabetes and obesity — were among reasons cited for the decrease.
Highmark’s diversified businesses, which include United Concordia Dental and HM Insurance Group, contributed $3.1 billion in consolidated operating revenue for the nine months.
The dental business reported a gain from operations of $75 million compared to $74 million a year ago and an operating gain of $55 million for the stop-loss business compared to $52 million in 2023. United Concordia and HM Insurance reported $1.3 billion and $907 million respectively in operating revenues for the period ending Sept. 30.
Highmark’s technology platform subsidiary company, enGen, another diversified Highmark business, reported $879 in operating revenue for the nine months, up 3.4% from $850 million in 2023.
Total revenue for Highmark’s biggest subsidiary, Allegheny Health Network, rose 9% to $3.8 billion for the nine months, while an operating loss of $88.1 million represented a 38.8% improvement from a year ago. Highmark Health is not a guarantor of AHN’s bonds, but continues to invest in the system as part of a clinical affiliation agreement.
For the nine months ending Sept. 30, Highmark Health invested $131 million in AHN as part of the agreement. AHN operates 14 hospitals, where admissions, emergency room visits and outpatient registrations all rose for the period.




Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.